Addendum by ECHS to Implementation Directives of ECHS Common Drug List (ECDL-2024) and Policy on Non Availability Certificate (NAC) for non CDL Drug
Tele: 25683476
Central Organisation ECHS
Integrated HQ of MoD (Army)
Adjutant General’s Branch
Thimayya Marg
Near Gopinath Circle
Delhi Cantt-110010
B/49769/AG/ECHS dated 10 Nov 2025
IHQ of MoD (Navy)/Dir ECHS (N)
Air HQ (DAV)/Coord
HQ Southern Command (A/ECHS)
HQ Eastern Command (A/ECHS)
HQ Western Command (A/ECHS)
HQ Central Command (A/ECHS)
HQ Northern Command (A/ECHS)
HQ South Western Command (A/ECHS)
HQ Andaman & Nicobar Command (A/ECHS)
All Regional Centres
ADDENDUM TO IMPLEMENTATION DIRECTIVES OF ECHS COMMON DRUG LIST (ECDL-2024) AND POLICY ON NON AVAILABILITY CERTIFICATE (NAC) FOR NON CDL DRUG
1. Please refer the following:-
1.1. Central Organisation ECHS letter No B/49769/AG/ECHS dated 31 Jul 2024 on the subject “Implementation Directives of ECHS Common Drug List (ECDL-2024)” (Copy attached).
1.2. Central Organisation ECHS letter No B/49761/AG/ECHS/Medicine Policy/2024 dated 12 Nov 2024 on the subject “Policy on Non Availability Certificate (NAC) for Non Drug Drugs” (Copy attached).
2. It is intimated that, the primary responsibility for provisioning of medicines and consumables rests with SEMO/SEDOs, who will continue to be the main source of centralized medicine supply.
3. As per Para 4 of the letter reference mentioned at Para 1,1.1 above, the ECHS Common Drug List (CDL) is dynamic in nature. New medicines may be added based on SEMO recommendations., subject to approval by Central Organisation ECHS. Furthermore, SEMOs are also authorised to procure anti-cancer and other vital life saving medicines even if they are not included in the ECDL.
4. SEMOs may exercise their emergency powers to procure these medicine on a patient specific and non bulk basis, limited to the required treatment duration. Polyclinics may forward requests for inclusion of such medicines in the ECDL with SEMOs recommendation. This process is applicable only to anti cancer and other life saving vital and essential drugs.
5. Any medicine deemed critical for a patient but not available in the ECDL may be sanctioned by Central Organisation ECHS after recommendation through the concerned SEMO. Such medicine will be added to the ECDL upon approval by MD COECHS. Formats for SEMO recommendation and sanction by MD, COECHS are enclosed as per appendix A and appendix B respectively for uniform implementation.
6. In view of the above, all concerned are requested to adhere strictly to the procedure outlined in the referenced policy letters and utilise the enclosed formats while seeking approval for procurement/ reimbursement of Non-CDL medicines. These instructions will come into effect from 07 Nov 2025. The contents of this communication may pl be disseminated to all ECHS polyclinics and Regional Centres under your AOR for necessary compliance.
This is the approval of MD, COECHS
Sd/-
(Vikas Yadav)
Lt Col
Jt Dir (Med & Eqpt)
for MD ECHS
Encls:– Appendix A & B and policy letters
COMMENTS